Fish oil triglycerides

(Omegaven®)

Omegaven®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 5 g/50 mL, 10 g/100 mL)
Drug ClassFatty acids
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Fish oil triglycerides (Omegaven) are indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). Omegaven has shown significant clinical advantages over other types of intravenous lipid emulsions (ILEs) in adult hospitalized patients, including reduced risks of infection and sepsis, and decreased hospital length of stay.
  • Four studies provided comprehensive assessments of the effectiveness and safety of Omegaven compared to other ILEs or interventions.
  • One study discussed the impact of omega-3 fatty acids supplementation on serum levels of brain-derived neurotrophic factor (BDNF). This suggests potential implications for neurological health and cognitive functions due to increased BDNF levels from omega-3 FAs found in Omegaven.
  • Another study focused on nutritional interventions for children under 5 years old in Ethiopia mentioned the potential benefits of fish oil supplementation, indicating possible roles for Omegaven within nutritional support contexts aimed at alleviating malnutrition consequences like wasting.
  • A review addressing the safety and efficacy of different lipid emulsions showed a significant reduction in cholestasis with fish oil LE like Omegaven compared to soybean-oil based LE among infants with gastrointestinal failure or PNALD. It also reported better weight gain but higher gamma-glutamyl transferase levels when using MOFS-based LE versus S-based ones; however, it concluded that there was insufficient data to prioritize any one type due to limitations such as small study sizes or early trial terminations.
  • The comparison between population/subgroup considerations shows superior safety/effectiveness against infections/sepsis/hospital stays duration among adults receiving parenteral nutrition, while promising results in reducing childhood wasting/improving nutritional status need further integrated approaches as advised by nutritional intervention studies.